Moleculin Biotech (NASDAQ:MBRX – Get Rating) and GlycoMimetics (NASDAQ:GLYC – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Moleculin Biotech and GlycoMimetics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moleculin Biotech | N/A | N/A | -$29.02 million | ($1.06) | -0.62 |
| GlycoMimetics | $80,000.00 | 1,517.91 | -$46.69 million | ($0.77) | -2.45 |
Moleculin Biotech has higher earnings, but lower revenue than GlycoMimetics. GlycoMimetics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moleculin Biotech | 0 | 0 | 2 | 0 | 3.00 |
| GlycoMimetics | 0 | 0 | 1 | 0 | 3.00 |
Moleculin Biotech presently has a consensus target price of $10.50, indicating a potential upside of 1,504.28%. GlycoMimetics has a consensus target price of $8.00, indicating a potential upside of 323.28%. Given Moleculin Biotech’s higher probable upside, research analysts clearly believe Moleculin Biotech is more favorable than GlycoMimetics.
Insider and Institutional Ownership
10.4% of Moleculin Biotech shares are held by institutional investors. Comparatively, 49.5% of GlycoMimetics shares are held by institutional investors. 3.7% of Moleculin Biotech shares are held by company insiders. Comparatively, 8.0% of GlycoMimetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Moleculin Biotech has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
Profitability
This table compares Moleculin Biotech and GlycoMimetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moleculin Biotech | N/A | -54.03% | -48.68% |
| GlycoMimetics | N/A | -81.16% | -70.15% |
Summary
Moleculin Biotech beats GlycoMimetics on 6 of the 11 factors compared between the two stocks.
About Moleculin Biotech
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
About GlycoMimetics
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
